ulcerative colitis
Continuous mucosal inflammation from the rectum proximally. Treatment follows extent and severity: mild–moderate → 5-ASA (rectal for proctitis, rectal + oral for left-sided, oral for extensive). Moderate–severe → steroids to induce, advanced therapy to maintain; infliximab + thiopurine is the strongest anti-TNF option. Acute severe UC (≥6 bloody stools + systemic toxicity) → admit, exclude C. difficile and CMV, IV methylprednisolone 60 mg, LMWH prophylaxis, reassess day 3 → infliximab or cyclosporine rescue or colectomy. Toxic megacolon → surgery.
severity and extent
Extent (Montreal): proctitis (E1) · left-sided, to splenic flexure (E2) · extensive, beyond splenic flexure (E3). Extent decides route of 5-ASA and CRC surveillance.
Severity (Truelove–Witts):
- mild: <4 stools/day, afebrile, normal HR, Hb >110 g/L, ESR <20
- severe: >6 bloody stools/day + ≥1 of fever, tachycardia, anaemia or raised ESR/CRP → admit
- moderate: in between
Treat to endoscopic improvement (Mayo 0–1), not symptoms alone. Calprotectin to track response and suspected relapse.
work-up of a flare
- Stool C. difficile for every new diagnosis and flare (clostridioides difficile infection); enteric pathogens.
- Colonoscopy with ileal intubation at diagnosis; biopsy normal-appearing proximal colon and rectum. Severe disease → flexible sigmoidoscopy only (perforation risk).
- No serology (ANCA/ASCA) for diagnosis or prognosis.
mild to moderate disease
| extent | induction | maintenance |
|---|---|---|
| proctitis | mesalamine suppository 1 g daily | same |
| left-sided | mesalamine enema ≥1 g daily + oral 5-ASA ≥2 g daily (suggested over oral alone) | oral 5-ASA ≥1.5 g (Toronto: ≥2 g) ± rectal |
| extensive | oral 5-ASA 2–2.4 g daily (4.8 g no better for mild) | oral 5-ASA ≥1.5 g |
- Rectal 5-ASA beats rectal steroids — mesalamine is first, topical steroid an add-on or if intolerant.
- Once-daily dosing equals divided dosing → choose once daily for adherence.
- Assess 5-ASA response at 4–8 weeks. Not responding → add budesonide MMX 9 mg or oral prednisone; don’t switch to another 5-ASA brand.
- Steroids never maintain remission (systemic, budesonide or topical).
- Proctitis is often undertreated with oral 5-ASA alone — it needs rectal therapy.
moderate to severe disease
Induction: budesonide MMX (moderate) or oral prednisone 40–60 mg/day → taper. Steroid-dependent, steroid-refractory or high-risk → advanced therapy.
Assess steroid response within 2 weeks and anti-TNF response at 8–12 weeks (Toronto 2015). Thiopurine or methotrexate alone don’t induce remission. Thiopurine is a reasonable maintenance after steroid induction in low-risk patients; methotrexate doesn’t maintain UC.
choosing an advanced therapy
All biologic classes, JAK inhibitors and S1P modulators are recommended. General choice (infection risk, vedolizumab vs adalimumab, loss of response, stopping 5-ASA), screening and safety → IBD advanced therapies. UC-specific points:
| situation | preferred |
|---|---|
| hospitalised or severe | infliximab + thiopurine (combination strongly recommended; infliximab usual inpatient choice) |
| prior anti-TNF failure, wants oral | upadacitinib or tofacitinib (CV risk factors → caution); ozanimod/etrasimod |
- Primary anti-TNF failure → switch to vedolizumab rather than another anti-TNF (Toronto 2015).
acute severe UC
acute severe UC admission bundle
- stool C. difficile + enteric pathogens; CBC, CRP, albumin, electrolytes, LFTs
- AXR — transverse colon >6 cm → toxic megacolon → urgent surgical consult
- flexible sigmoidoscopy within 72 h (ideally 24 h) with biopsies for CMV
- IV methylprednisolone 60 mg/day (or hydrocortisone 100 mg TID–QID)
- LMWH prophylaxis despite rectal bleeding
- pre-infliximab screen now (HBV, TB, HIV, VZV) → IBD advanced therapies
- stop NSAIDs, opioids, anticholinergics, antidiarrhoeals
- correct K⁺ and Mg²⁺ (and before cyclosporine)
- no routine antibiotics; no TPN for bowel rest
- colorectal surgery consult on admission
- daily stool count, blood, abdominal exam, CRP
- day 3: >8 stools, or 3–8 stools + CRP >45 → rescue therapy or colectomy
Day-3 decision (Oxford criteria above → ~85% colectomy without rescue):
- Infliximab 5 mg/kg; consider 10 mg/kg if albumin <25 g/L (protein-losing colon clears drug); accelerated induction lacks long-term benefit. Don’t give sequential cyclosporine → infliximab rescue. Continue infliximab as maintenance if it works.
- Cyclosporine 2 mg/kg/day IV → oral; bridge to thiopurine or vedolizumab maintenance. Choose by local experience, prior thiopurine failure (cyclosporine needs a thiopurine to bridge to), and low albumin and cholesterol (cyclosporine neurotoxicity).
- No response to rescue in 5–7 days, or deterioration at any time → colectomy. Infliximab or cyclosporine exposure doesn’t increase surgical complications — don’t delay surgery for it.
- JAK inhibitors as rescue: insufficient data for routine use.
CMV colitis — up to a third of steroid-refractory ASUC. Diagnose by biopsy immunohistochemistry or tissue PCR (serum PCR poor). Treat with ganciclovir; don’t hold colectomy while treating.
Perforation or massive haemorrhage → colectomy. Toxic megacolon (transverse colon >6 cm + systemic toxicity) → urgent surgical consult; usually colectomy (ACG lists it as a surgical indication).
long-term care
- CRC surveillance colonoscopy from 8 years after diagnosis in colitis beyond the rectum; PSC → from diagnosis, every 1–2 years. Controlling inflammation lowers dysplasia risk. A first-degree relative with CRC adds risk — family-history screening rules → cancer screening — Canadian guidelines.
- PSC: proximal-predominant colitis with relative rectal sparing; cholestatic LFTs → MRCP (primary biliary and sclerosing cholangitis).
- Smoking is protective in UC, but cessation is still advised.
- Bone health, anaemia, vaccines and pre-therapy screening → IBD advanced therapies.
- Screen for anxiety and depression.
- Distinguishing UC from Crohn’s → Crohn’s disease.
Prepared 2026-10-28. Not yet verified — check every number against the sources.